estimate the ratio of incremental expected cost of ramipril therapy to the incremental life year gained (LYG). All costs were discounted at 3% per year. RESULTS: Discounted cost for within-trial CE analysis was $2600 for ramipril compared to $1554 for placebo (incremental cost, $1046) . With a 2% absolute risk reduction in within-trial cardiac mortality, the incremental cost/LYG was $11,622. Cost/LYG under the persistent benefit was $4509. For extended benefit of therapy, cost/LYG was $4014. Sensitivity analysis ranged from cost/LYG of $3143 to $12,689. CONCLUSIONS: Ramipril is CE in preventing CV events in high-risk patients across multiple therapy benefit scenarios. 
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HOSPITAL COSTS AND CHARGES ATTRIBUTABLE TO THE DEVELOPMENT OF ARI/ARF AFTER CABG
OBJECTIVES:
To estimate hospital costs and charges attributable to the development of acute renal insufficiency (ARI) and acute renal failure (ARF) after coronary artery bypass grafting (CABG). METHODS: A retrospective analysis of patients undergoing CABG at University of Pittsburgh Medical Center from June 1998 through May 2002 was conducted. Patients were matched with respect to severity of illness by APACHE III scores. A Wilcoxon signed-rank test was used to assess differences in costs and charges. RESULTS: There were 3741 total patients that resulted in 644 matched pairs. The mean and median hospital charges among cases were approximately $221,864 and $158,312 respectively. The mean and median hospital charges among controls were approximately $110,868 and $91,738 respectively. Distribution of the hospital charges were positively skewed (Shapiro-Wilk test, 0 < 0.001). The difference in median hospital charges was $66,500 (Wilcoxon signed-rank test, p < 0.01). The mean and median hospital costs among cases were $44,180 and $28,901 respectively. The mean and median hospital costs among controls were $22,471 and $18,038 respectively. The difference in median hospital costs was $10,863 (Wilcoxon signed-rank test, p < 0.01). The mean and median ICU costs among cases were $35,566 and $21,183 respectively. The mean and median ICU costs among controls were $17,634 and $13,655 respectively. The difference in median ICU costs was $7528 (Wilcoxon signed-rank test, p < 0.01). CONCLU-SIONS: Although patients were matched using APACHE III scores, a severity of illness scoring system, patients with ARI/ARF after CABG had significantly higher hospital and ICU costs and charges than patients without ARI/ARF. These differences can be attributed to the development of renal complications after CABG.
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COST EFFECTIVENESS STUDY OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR VS. CONVENTIONAL TREATMENT IN PREVENTING SUDDEN DEATH AMONG PATIENTS WITH HEART FAILURE
Chen L, Hay JW University of Southern California, Los Angeles, CA, USA Sudden death is one of the two main causes of mortality in congestive heart failure. Implanted cardioverter defibrillator (ICD) is an expensive but highly effective treatment in preventing sudden death. The gain of primary prophylactic ICD in preventing sudden death in heart failure has not been clearly established. OBJECTIVE: Compare the cost-effectiveness of prophylactic ICD with conventional treatment for preventing sudden death. METHODS: A lifetime decision model was built. The perspective is societal. The target population is U.S. HF patients, aged 60, with NYHA functional Class II and III. Estimates of cost, utility and probabilities are taken from literature, clinical experts, CMS fee schedule payment, and the Bureau of Labor Statistics. In all cases, we assume that ICD is effective in preventing all sudden death, and the ICD would be reimplanted at ninth year. In our base case, we assume that total annual mortality rate is 20%, of which sudden death accounts for 40%; the utility of ICD is 10% less during the 1st year after implantation, and reverts back to pre-implantation level in the 2nd year. We did a one-way sensitivity analyses on all model parameters. RESULTS: the lifetime cost is $117,095 for patients with prophylactic ICD and $24,709 for patients with conventional treatment in 2002; the QALYs gained were 2.9088 and 1.9045 respectively. The CE ratio was $91,990 per QALY saved. We failed to show that ICD is cost-effectiveness under any plausible scenario if we use $50,000 per quality-adjusted-life-year saved as the cut-off point. CE ratio is sensitive to the utility at the second and subsequent years after ICD implantation, and the proportion of sudden death in all HF-related deaths. CONCLUSIONS: Using conventional cost effectiveness benchmarks of $50,000 per life year saved, it is unlikely that ICD would be cost-effectiveness in preventing sudden death compared to conventional treatment for heart failure patients. Future research should focus on patient utility with and without ICD.
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PREDICTING THE BURDEN OF CONGESTIVE HEART FAILURE (CHF) IN A MANAGED CARE SETTING: A NEW MODEL TO PREDICT OUTCOMES AND EVALUATE THE COST-BENEFIT OF CHF MANAGEMENT
Joglekar A, Chao C, Kadison P Medical Scientists, Inc, Boston, MA, USA OBJECTIVES: Previous studies have used Markov models to predict future CHF hospitalizations based on a patient's multiple prior admissions. Our objective is to develop a model that predicts future admissions based on left ventricular ejection fraction (LVEF) and the occurrence of a CHF admission in the preceding quarter. Another objective is to use this model to examine, in a managed care setting, the cost-benefit of the following CHF management strategies: ACE inhibitor therapy, beta blocker therapy, CHF disease management, and intensive case management. METHODS: We constructed a Markov model to project the medical and non-medical costs for a cohort of CHF patients in a commercially insured population. The model defines four disease states based on LVEF status (normal vs. low) and a prior admission (yes vs. no) in the preceding quarter. The probability of a future admission depends on the patient's disease state as well as age and gender. Plan-specific CHF admission probabilities were calibrated using claims analyses. Each intervention is assumed to change health service utilization patterns and improve survival. Cost-benefit is expressed as net savings in medical and non-medical costs. RESULTS: For a population of 100,000 commercially insured individuals, CHF case rate and medical costs are predicted to increase steadily over the next 5 years. Intensive case management appears to be the most cost-beneficial intervention, with an estimated per member per month (PMPM) net savings of $0.11 in the first year. Beta blocker therapy is expected to save $0.08 in the first year, while ACE inhibitors and CHF disease management show net positive savings starting year 2. All interventions remain cost-beneficial when non-medical savings are eliminated from the analyses. CONCLU-SIONS: The four CHF management strategies modeled are not only effective in improving clinical outcomes; they are also predicted to be cost-beneficial in a managed care setting. 
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EVALUATION ON THE COST OF MANAGEMENT OF ACUTE MYOCARDIAL
